Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets: 2018-2025

Historic Current Assets for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $738.8 million.

  • Bicycle Therapeutics' Current Assets fell 23.53% to $738.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.8 million, marking a year-over-year decrease of 23.53%. This contributed to the annual value of $928.6 million for FY2024, which is 65.27% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Current Assets stood at $738.8 million for Q3 2025, which was down 8.14% from $804.3 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Current Assets ranged from a high of $1.0 billion in Q2 2024 and a low of $215.4 million during Q1 2021.
  • Moreover, its 3-year median value for Current Assets was $738.8 million (2025), whereas its average is $708.4 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Current Assets soared by 194.47% in 2021 and then declined by 23.53% in 2025.
  • Bicycle Therapeutics' Current Assets (Quarterly) stood at $458.6 million in 2021, then declined by 19.45% to $369.4 million in 2022, then spiked by 52.11% to $561.9 million in 2023, then surged by 65.27% to $928.6 million in 2024, then fell by 23.53% to $738.8 million in 2025.
  • Its Current Assets was $738.8 million in Q3 2025, compared to $804.3 million in Q2 2025 and $856.1 million in Q1 2025.